The Phase 3 SAFFRON trial met its primary endpoints, showing that investigational savolitinib plus osimertinib significantly improved both PFS and OS versus platinum-based chemotherapy for patients with EGFR-mutated NSCLC with MET overexpression/amplification after progression on osimertinib. Additionally, the Phase 3 DESTINY-Lung04 trial demonstrated that investigational trastuzumab deruxtecan (T-DXd) improved PFS compared to pembrolizumab plus platinum-based chemotherapy in the first-line setting for metastatic HER2-mutant NSCLC. Discussion is also noting a JTO update on harmful outcomes of neoadjuvant chemoimmunotherapy in poorly selected patients with stage III NSCLC.
“🚨 Phase 3 SAFFRON met its primary endpoint Savolitinib + osimertinib significantly improved PFS and OS vs. platinum-based chemo in EGFRm NSCLC with MET overexpression/amplification after progression on osimertinib.”
— @M_Torasawa · SAFFRON trial results · View post ↗
“JUST IN (again, today!) and also from @AstraZeneca: DESTINY-Lung04 Phase III trial showed T-DXd (trastuzumab deruxtecan) PFS > chemo+pembro in FIRST-LINE metastatic HER2-mutant lung cancer (2-4% of all NSCLC)”
— @DrChoueiri · DESTINY-Lung04 trial results · View post ↗📌 Amplified by @KolPulseAI
“The key question now is sequencing: ADC first, or the emerging HER2-selective TKIs? OS and full data will matter.”
— @dr_yakupergun · HER2m NSCLC sequencing · View post ↗📌 Amplified by @KolPulseAI
“NEW: An update on the harmful consequences of neoadjuvant chemoimmunotherapy in poorly selected pts with stage III NSCLC.”
— @DrewMoghanaki · Neoadjuvant chemoimmunotherapy · View post ↗A study in JCO Precision Oncology characterizes primary breast neuroendocrine carcinoma (NEC) as biologically distinct, with near-universal Rb loss (93%), enrichment for concurrent TP53/RB1 alterations (50%), and 0% pathologic complete response to neoadjuvant chemotherapy. Separately, real-world data on metastatic breast cancer post-T-DXd suggests switching the chemotherapy's mechanism of action is the most effective strategy, while the benefit of early ctDNA-guided intervention in triple-negative breast cancer remains uncertain.
“what works best among patients with MBC and prior T-DXd? (Unsurprising) answer: switching mechanism of action of the chemo.”
— @PTarantinoMD · Post-T-DXd Sequencing · View post ↗📌 Amplified by @KolPulseAI
“Supports classifying breast NEC as a true high-grade NEC (akin to extramammary sites) rather than just “breast cancer with NE features.””
— @sonbol_bassam · Breast Neuroendocrine Carcinoma (NEC) · View post ↗
“In summary, benefits of early MRD detection/intervention remain uncertain & prospective ctDNA-guided intervention studies are needed.”
— @DarcyBurbage · ctDNA in Early TNBC · View post ↗📌 Amplified by @KolPulseAI
An algorithm for first-line metastatic colorectal cancer (mCRC) treatment selection highlights key decision drivers including MSI/MMR status, BRAF/RAS mutation status with tumor sidedness, and reassessment of resectability. Separately, an upcoming symposium will focus on young adult cancers, including colorectal and genitourinary malignancies, and supportive care.
“1L mCRC: what drives choice? 🔵 MSI/MMR 🔵 BRAF/RAS + sidedness 🔵 Reassess resectability/maintenance”
— @OpenMedInsights · mCRC Treatment Algorithm · View post ↗
“2nd Annual Vanderbilt-Ingram Young Adult Cancer Symposium, C-Beyond: Thriving Through Young Adult Cancer: #colorectal + #genitourinary #cancer + #SupportiveCare #advocacy”
— @CathyEngMD · Young Adult Cancer Symposium · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
In favorable intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) with 5 fractions was not superior to 20–28 fractions for 3-year disease control, though it offers greater convenience. For urothelial cancer, high blood levels of IL-6/CRP are associated with an immunosuppressive tumor microenvironment, suggesting a potentially targetable axis of resistance to immunotherapy.
“In favorable intermediate-risk prostate cancer, SBRT was far more convenient, but not superior for 3-year disease control.”
— @DrYukselUrun · Prostate Cancer SBRT · View post ↗
“High IL-6/CRP tracks with SPP1⁺ macrophage–rich, T-cell–suppressed tumors in urothelial cancer across ICB cohorts.”
— @drenriquegrande · Urothelial Cancer Biomarkers · View post ↗
“New in #practicalRO: Cumulative incidence of toxicity between 2 and 5 years following SBRT to the prostate and pelvis nodes in patients with high-risk prostate cancer.”
— @ASTRO_org · SBRT Toxicity · View post ↗A retrospective study of 640 patients with relapsed/refractory multiple myeloma (RRMM) found that using CAR-T therapy, primarily cilta-cel, before bispecific antibodies resulted in longer PFS. Separately, discussion from the #SeattleCT26 summit on choosing between cilta-cel and teclistamab-daratumumab at first relapse concluded there is no single right answer, but recommended early involvement of a CAR-T center to preserve future options.
“Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality or Sequential Strategies in RRMM. Retrospective data from 640 patients. Conclusion: Use both, but CAR-T (mainly cilta-cel) first due to longer PFS”
— @Transplant_Doc · CAR-T vs. Bispecific Sequencing · View post ↗📌 Amplified by @KolPulseAI
“Cilta-cel vs tec-dara in myeloma #MMsm at 1st relapse Quoting from his slide: 1️⃣ No single right answer 2️⃣ Even if tec-dara chosen, involve CAR-T center to keep future options as open as possible”
— @RahulBanerjeeMD · Therapy Choice at 1st Relapse · View post ↗📌 Amplified by @KolPulseAI
Menin inhibition is being highlighted as a therapeutic strategy for AML with KMT2A rearrangements or NPM1 mutations, acting as a differentiation therapy by blocking the menin–KMT2A interaction to suppress the HOXA/MEIS1 transcriptional program. Other topics include a meta-analysis on survival by ctDNA and PET response in large B-cell lymphoma and a special issue in Human Pathology covering contemporary AML diagnosis, multimodal MRD detection, and single-cell technologies.
“Menin inhibition has rapidly moved from a biological concept to an established therapeutic strategy in AML.”
— @TalhaBadarMD · Menin inhibitors · View post ↗📌 Amplified by @KolPulseAI
“A master review by the one and only @jadothm, George Mason and Ameya Hanamshet a, on Multimodal MRD detection in AML: From technology to clinical integration”
— @sanamloghavi · MRD in AML · View post ↗
“Meta-analysis of survival by phased-variant #ctDNA and PET response in large B-cell #lymphoma”
— @DrRaulCordoba · ctDNA in LBCL · View post ↗📌 Amplified by @KolPulseAI